Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics, Inc. (AKRO) Form 4 filing: Chief Technology Officer Scott A. Gangloff disclosed an automatic sale of 848 shares of common stock on 18 June 2025 at a weighted-average price of $54.84 per share. The transaction was executed under the company’s mandatory “sell-to-cover” policy to satisfy tax-withholding obligations triggered by the vesting of restricted stock units, meaning it was not a discretionary trade. After the sale, the executive continues to hold 23,452 shares directly.